Chemomab Therapeutics Ltd (CMMB)
0.64
-0.03
(-4.48%)
USD |
NASDAQ |
Apr 25, 16:00
0.64
0.00 (0.00%)
After-Hours: 20:00
Chemomab Therapeutics Net Income (TTM): -33.08M for June 30, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2023 | -33.08M |
| March 31, 2023 | -31.30M |
| December 31, 2022 | -27.65M |
| September 30, 2022 | -24.41M |
| June 30, 2022 | -19.30M |
| March 31, 2022 | -15.88M |
| Date | Value |
|---|---|
| December 31, 2021 | -12.48M |
| September 30, 2021 | -9.393M |
| June 30, 2021 | -7.649M |
| March 31, 2021 | -5.96M |
| December 31, 2020 | -5.951M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-33.08M
Minimum
Jun 2023
-5.951M
Maximum
Dec 2020
-17.55M
Average
-15.88M
Median
Mar 2022
Net Income (TTM) Benchmarks
| Compugen Ltd | -18.75M |
| Pluri Inc | -23.95M |
| BioLine Rx Ltd | -60.61M |
| Can Fite Biofarma Ltd | -7.634M |
| BiomX Inc | -26.17M |